Company Overview
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Why Investors Should Care
Revenue has grown at a 28.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $21.05M (-79.1% YoY); net profit $-142.93M.
- Trailing 12 Months Year-on-year growth — revenue -71.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 28.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 28.27% |
| 1 Year: | -71.50% |
Stock Price Performance
| 1 Year: | +12.84% |
| 6 Months: | +23.00% |
| 3 Months: | +50.46% |
| 1 Month: | +34.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.12 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 28.3% over 5 years.
CONS
- Trading 25.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALEC Alector, Inc. R2KR3KPHARMA | 2.46 | -2.07 | $273.12M | 0.00% | -69.73% | - | 28.27% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.75M | 7.11M | 6.50M | - | 5.61M | 6.92M | 2.70M | - | 7.17M | 3.17M | 5.90M | 4.11M | 6.57M | 182.41M | 24.47M | 79.85M | 14.85M | 16.55M | 56.21M | 9.11M | 15.89M | 15.08M | 15.34M | 3.67M | 7.87M | 3.26M | 6.24M | 1.05M | 3.32M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 48.37M | 42.01M | 40.87M | 45.80M | 25.96M | - |
| Operating Income | -9.22M | -12.23M | -16.82M | -19.02M | -20.76M | -27.15M | -34.15M | -32.34M | -42.08M | -46.59M | -53.75M | -52.63M | -55.33M | 126.33M | -44.12M | 9.47M | -47.75M | -50.12M | -3.59M | -50.58M | -43.71M | -45.61M | -48.43M | -44.70M | -34.14M | -37.61M | -39.57M | -24.92M | -24.39M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -42.85M | -30.92M | -35.28M | -37.31M | -22.84M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -40.47M | -30.52M | -34.67M | -37.10M | -22.93M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 168.00K | 0 | - |
| Net Income | -8.44M | -11.12M | -15.32M | -17.37M | -18.56M | -24.56M | -31.74M | -30.53M | -40.02M | -45.33M | -52.70M | -52.17M | -55.15M | 126.60M | -44.62M | 9.88M | -46.15M | -45.86M | 1.38M | -44.48M | -36.08M | -38.68M | -42.22M | -40.47M | -30.52M | -34.67M | -37.27M | -22.93M | -22.99M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.67 | - | -0.69 | 1.49 | -0.54 | 0.12 | -0.56 | -0.55 | 0.02 | -0.53 | -0.38 | -0.40 | -0.43 | -0.41 | -0.30 | -0.34 | -0.34 | -0.21 | -0.21 |
| R&D Expense | 11.72M | 16.82M | 20.39M | - | 20.61M | 25.64M | 28.52M | - | 34.60M | 34.06M | 43.82M | 45.73M | 47.82M | 43.07M | 53.04M | 54.53M | 48.35M | 51.89M | 46.18M | 46.33M | 45.17M | 46.31M | 48.00M | 33.64M | 27.61M | 29.35M | - | 17.86M | 19.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.87M | 27.51M | 21.22M | 21.10M | 207.09M | 133.62M | 97.06M | 100.56M | 21.05M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 271.45M | 248.80M | 245.56M | 177.05M |
| Operating Income | -32.68M | -57.29M | -114.40M | -195.17M | -37.36M | -137.83M | -151.74M | -145.00M | -156.01M |
| EBITDA | - | - | - | - | - | -129.36M | -142.89M | -136.16M | -146.35M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | -130.06M | -125.18M | -118.92M | -142.76M |
| Tax Provision | - | - | - | - | - | 3.25M | 5.21M | 128.00K | 168.00K |
| Net Income | -32.48M | -52.25M | -105.39M | -190.23M | -36.33M | -133.31M | -130.39M | -119.05M | -142.93M |
| Diluted EPS | - | - | - | -2.45 | -0.45 | -1.62 | -1.56 | -1.23 | -1.39 |
| R&D Expense | 29.91M | 73.03M | 100.53M | 156.87M | 189.41M | 210.42M | 192.12M | 185.94M | 123.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 308.36M | 421.91M | 488.25M | - | 787.65M | 621.83M | 468.30M | 293.24M |
| Current Assets | - | - | - | - | - | - | 726.43M | 565.81M | 424.82M | 266.45M |
| Cash & Equivalents | - | 32.45M | 65.47M | 89.64M | 49.97M | - | 154.32M | 74.56M | 33.02M | 65.80M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 7.39M | 2.59M | 0 | - | - |
| Total Liabilities | - | - | 195.24M | 227.17M | 220.72M | - | 573.21M | 487.67M | 341.50M | 262.59M |
| Current Liabilities | - | - | 47.95M | 61.97M | 68.09M | - | 93.81M | 177.95M | 125.06M | 69.50M |
| Long Term Debt | - | - | - | - | - | - | - | - | 9.39M | 9.32M |
| Total Debt | - | - | - | - | - | - | 43.33M | 38.92M | 42.52M | 36.23M |
| Total Equity | -24.91M | -52.03M | -97.40M | 194.74M | 267.53M | - | 214.44M | 134.16M | 126.80M | 30.65M |
| Shares Outstanding | - | - | - | - | - | - | 82.90M | 84.88M | 99.09M | 110.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.77M | 127.46M | -99.31M | -166.73M | - | -20.33M | -184.16M | -229.91M | -184.03M |
| Investing Cash Flow | -801.00K | -224.12M | -48.87M | -105.05M | - | -159.01M | 101.92M | 107.13M | 196.60M |
| Financing Cash Flow | -15.00K | 131.15M | 172.35M | 232.11M | - | 4.51M | 2.55M | 81.54M | 20.21M |
| Capital Expenditure | -801.00K | -1.88M | -15.27M | -5.03M | - | -4.12M | -2.38M | -1.25M | -41.00K |
| Free Cash Flow | -18.57M | 125.58M | -114.57M | -171.77M | - | -24.45M | -186.54M | -231.16M | -184.07M |
| Net Change in Cash | - | - | - | - | - | -174.83M | -79.69M | -41.23M | 32.78M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -1,137.8% | -208.3% | -539.2% | -925.1% | -18.0% | -103.2% | -156.3% | -144.2% | -741.3% |
| Net Margin % | -1,130.9% | -189.9% | -496.7% | -901.6% | -17.5% | -99.8% | -134.3% | -118.4% | -679.2% |
| ROE % | 62.4% | 53.6% | -54.1% | -71.1% | - | -62.2% | -97.2% | -93.9% | -466.3% |
| ROCE % | - | -22.0% | -31.8% | -46.5% | - | -19.9% | -34.2% | -42.2% | -69.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 8.96% | 10.00M | $23.40M |
| 2 | Blackrock Inc. | 7.03% | 7.85M | $18.36M |
| 3 | Acadian Asset Management. LLC | 3.95% | 4.41M | $10.33M |
| 4 | Nantahala Capital Management, LLC | 3.87% | 4.32M | $10.10M |
| 5 | Vanguard Capital Management LLC | 3.59% | 4.01M | $9.38M |
| 6 | Kynam Capital Management, LP | 3.41% | 3.81M | $8.91M |
| 7 | Merck & Co., Inc. | 3.18% | 3.55M | $8.30M |
| 8 | Balyasny Asset Management LP | 2.91% | 3.25M | $7.60M |
| 9 | 683 Capital Management LLC | 2.87% | 3.20M | $7.49M |
| 10 | Shaw D.E. & Co., Inc. | 2.65% | 2.96M | $6.93M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALEC
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced t…
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer’s disease (AD). Continued…
GSK ends brain drug alliance with Alector
Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.
Alector (ALEC) Stock Faces Mixed Analyst Target Changes On Tau Therapy Readthrough
Alector’s latest update leaves the model fair value steady at US$3.10 per share, so headline price target assumptions are unchanged even as inputs inside the model continue to move. Analysts are linking this steady fair value to shifting se…
How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus
Alector’s updated analyst framework now points to a fair value move from US$2.88 to US$3.10, a modest shift that still signals a meaningful recalibration of expectations. This change is closely tied to how analysts are weighing CELIA’s read…
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of +40.00% and -65.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
ALEC — Frequently Asked Questions
What is the current share price of Alector, Inc. (ALEC)?
As of 2026-09-07 16:24 PDT, Alector, Inc. (ALEC) trades at $2.46 on NasdaqGS. Its 52-week range is $1.14 to $3.32.
What is the market capitalisation of ALEC?
Alector, Inc. (ALEC) has a market capitalisation of $273.12M on NasdaqGS.
What is the P/E ratio of ALEC?
ALEC trades at a trailing price-to-earnings (P/E) ratio of -2.07. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.40.
Is ALEC a good stock to buy?
This page provides a data-driven analysis of Alector, Inc. (ALEC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.